HLB Pharma Acquires Rights to Hyperlipidemia Treatment 'Rosuduo'

HLB Pharmaceutical is strengthening its foundation for sustainable growth by acquiring full rights to its flagship product, the hyperlipidemia treatment ‘Rosuduo’.

Rosuduo is a representative pharmaceutical product driving HLB Pharmaceutical’s rapid growth, having achieved sales exceeding 10 billion KRW based on cumulative sales as of November this year from a single product. Thanks to the steep growth of prescription drugs, HLB Pharmaceutical’s cumulative sales for the third quarter surpassed 100 billion KRW for the first time since its establishment, demonstrating rapid growth even in the recently sluggish pharmaceutical environment.

At the end of last year, HLB Pharmaceutical succeeded in the bioequivalence test for Rosuduo, establishing a foundation to maintain a stable drug price level compared to competitors. By permanently acquiring all rights to the drug from Seorseu Pharmaceutical, the supplier of the product, long-term stable supply of Rosuduo has become possible. Potential risks related to sales rights in the future have also been reduced.

Considering the growth rate of the hyperlipidemia treatment market and the sales trend of Rosuduo, HLB Pharmaceutical expects to achieve sales exceeding 20 billion KRW from this product alone within a few years.

Kim Man-gyu, Vice President in charge of the pharmaceutical business division, said, "With the complete acquisition of rights to Rosuduo, we have been able to improve costs as well as enhance product competitiveness." He added, "Along with the sales of pharmaceuticals including Rosuduo, sales in the CMO business through the Hyangnam plant are also rapidly increasing," and forecasted, "An annual growth rate exceeding 50% is expected to continue going forward."

This content was produced with the assistance of AI translation services.